Kinsale Capital Group Inc. Has $3.46 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Kinsale Capital Group Inc. increased its position in Humana Inc. (NYSE:HUM) by 15.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,626 shares of the insurance provider’s stock after buying an additional 1,849 shares during the period. Kinsale Capital Group Inc.’s holdings in Humana were worth $3,457,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV grew its stake in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the period. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the 4th quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Humana in the 3rd quarter valued at about $31,000. Finally, Atwood & Palmer Inc. grew its stake in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

Humana stock opened at $270.91 on Friday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The business’s 50 day simple moving average is $271.11 and its 200 day simple moving average is $286.85. The company has a market cap of $32.68 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.31%. Humana’s payout ratio is 35.58%.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on HUM. Piper Sandler raised their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Barclays raised their price target on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company dropped their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.